Rhinophyma in women: a case series

Ismail, D.; Asfour, Leila; Madan, Vishal

doi:10.1007/s10103-020-03183-z

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the pharmaceutical agents, isotretinoin has been associated with better prognosis of rhinophyma and the shrinkage of the overall volume of phymata by reducing the size of the sebaceous glands. Although it does not appear to be a curative option, it could represent a good strategy after laser treatment to prevent relapse [155,156].…”

Section: Phymatous Changesmentioning

confidence: 99%

Advances in the Pathogenesis and Treatment of Rosacea: A Phenotype-Based Therapeutic Approach

Galluccio,

D’Onghia,

Malvaso

et al. 2024

Cosmetics

View full text Add to dashboard Cite

Rosacea is a common chronic inflammatory skin disorder that mainly affects the central face. It is primarily characterized by recurrent episodes of flushing, persistent erythema, inflammatory papules, telangiectasias, phymatous changes, and ocular symptoms. Its pathogenesis is complex and still not completely understood. It encompasses innate and adaptive immune system dysregulation, neurovascular dysfunction, and genetic and environmental factors. To date, four subtypes of rosacea have been identified, based on the predominant clinical features: erythemato-teleangiectatic, papulopustular, pyhomatous, and ocular rosacea. New insights into this condition have led to several pharmacological treatments, including topical medications, spanning from the conventional azelaic acid, metronidazole, benzoyl peroxide, clindamycin, and erythromycin to new ones including not only brimonidine, oxymetazoline, ivermectine, and minocycline but also systemic drugs such as oral antibiotics, isotretinoin, non-selective β-blockers or α2-adrenergic agonists, and laser- or light-based therapies, together with new therapeutic approaches. The aim of this study was to review the current literature on the pathophysiology of rosacea and to provide an overview of therapeutic approaches that specifically address each clinical subtype.

show abstract

Section: Phymatous Changesmentioning

confidence: 99%

Advances in the Pathogenesis and Treatment of Rosacea: A Phenotype-Based Therapeutic Approach

Galluccio,

D’Onghia,

Malvaso

et al. 2024

Cosmetics

View full text Add to dashboard Cite

show abstract

Rosacea

van Zuuren,

Tan,

van der Linden

et al. 2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

Rosacea is a chronic inflammatory disease affecting the cheeks, chin, nose, forehead and frequently the eyes. Recent advances have emphasised the roles of the innate and adaptive immune systems and neurovascular dysregulation underlying the spectrum of clinical features of rosacea. This chapter covers the phenotype‐based diagnosis and classification system as well as management options based on the latest evidence. Recommendations for management of paediatric rosacea and management of pregnant or lactating women are included. Furthermore, differential diagnoses and facial dermatoses with an uncertain nosological relationship to rosacea will be discussed.

show abstract

Rosacea: Treatment targets based on new physiopathology data

Cribier

2022

Annales de Dermatologie et de Vénéréologie

View full text Add to dashboard Cite

Rhinophyma in women: a case series

Cited by 4 publications

References 24 publications

Advances in the Pathogenesis and Treatment of Rosacea: A Phenotype-Based Therapeutic Approach

Advances in the Pathogenesis and Treatment of Rosacea: A Phenotype-Based Therapeutic Approach

Rosacea

Rosacea: Treatment targets based on new physiopathology data

Contact Info

Product

Resources

About